Larimar Therapeutics, Inc. (LRMR) Misses Q1 EPS by 3c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q1 EPS of ($0.27), $0.03 worse than the analyst estimate of ($0.24).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold
• Barclays says AI trade is maturing, favors greater diversification